Immunogenicity of Influenza Vaccine in Colorectal Cancer Patients.
- Author:
Dong Ho KIM
1
;
Yun Yong LEE
;
Ui Sup SHIN
;
Sun Mi MOON
Author Information
1. Department of Pediatrics, Korea Cancer Center Hospital, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Colorectal neoplasms;
Human influenza;
Influenza vaccines;
Hemagglutination inhibition tests
- MeSH:
Cohort Studies;
Colorectal Neoplasms*;
Hemagglutination Inhibition Tests;
Humans;
Immunocompromised Host;
Influenza Vaccines*;
Influenza, Human*;
Korea;
Mortality;
Seasons;
Vaccination
- From:Cancer Research and Treatment
2013;45(4):303-312
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Although influenza is regarded as a major cause of morbidity and mortality in immunocompromised patients, vaccine coverage remains poor. We evaluated the immunogenicity of influenza vaccines in colorectal cancer patients. MATERIALS AND METHODS: In this study, 40 colorectal cancer patients who received an influenza vaccine at the Korea Cancer Center Hospital during the 2009-2010 and 2010-2011 influenza seasons were analyzed. The blood samples were collected at prevaccination and 30 days post vaccination, and antibody titers were measured using the hemagglutination-inhibition tests. RESULTS: In the 2009-2011 season, the seroprotection rate for H1N1 (94.7%) was significantly higher than that for H3N2 (42.1%) and B (47.3%). The seroconversion rate was 52.6%, 26.3%, and 36.8% for H1N1, H3N2, and B, respectively. Fold increase of geometric mean titer (MFI) was 3.86, 1.49, and 3.33 for H1N1, H3N2, and B, respectively. In the 2010-2011 season, the seroprotection rate for H1N1 (57.1%) was significantly higher than that for H3N2 (52.4%) and B (38.1%). The seroconversion rate was 52.4%, 47.6% and 33.3% for H1N1, H3N2, and B, respectively. MFI was 12.29, 3.62 and 4.27 for H1N1, H3N2, and B, respectively. CONCLUSION: Our study cohort showed an acceptable immune response to an influenza vaccine without significant adverse effects, supporting the recommendation for annual influenza vaccination in colorectal cancer patients.
